新前列腺癌易感基因SP6与侵袭性疾病风险相关
该研究对芬兰2738例病例和2400例对照的185478个SNP进行全基因组分析,发现21个低外显率易感位点,其中10个为新位点。SP6内含子变异rs2074187不仅与总体前列腺癌风险相关(OR 1.66),还与侵袭性前列腺癌风险升高相关(OR 1.89)。
要点
- SP6 rs2074187与前列腺癌总体风险相关(OR 1.66)。
- SP6 rs2074187与侵袭性前列腺癌风险升高相关(OR 1.89)。
- 8q24区新变异rs79012498增加侵袭性前列腺癌风险。
核心结论
- SP6是新的前列腺癌候选易感基因,其变异与侵袭性疾病风险相关。
研究设计与样本
- 全基因组关联分析,芬兰样本2738例病例和2400例对照,检测185478个SNP,来自iCOGS研究。
主要发现
- 共鉴定21个常见低外显率易感位点,其中10个为新变异且独立与前列腺癌风险相关。
- SP6内含子变异rs2074187与总体前列腺癌风险相关(OR 1.66),与侵袭性前列腺癌风险相关(OR 1.89),与非侵袭性前列腺癌风险相关(OR 1.43)。
- 8q24区基因间变异rs79012498增加侵袭性前列腺癌风险(OR 1.81,padj = 4.26 × 10-8)。
关键数值与推荐
- SP6 rs2074187:总体前列腺癌OR 1.66,侵袭性前列腺癌OR 1.89,非侵袭性前列腺癌OR 1.43。
- 8q24区CASC8 rs16902147:OR 1.86,padj = 3.53 × 10-8。
- 8q24区rs58809953:OR 1.71,padj = 4.00 × 10-6。
- 8q24区基因间rs79012498:OR 1.81,padj = 4.26 × 10-8。
- 17q21区SP6 rs2074187:OR 1.66,padj = 3.75 × 10-5。
临床怎么用
- SP6 rs2074187等位点可能作为前列腺癌风险分层和侵袭性风险评估的候选遗传标记。
局限性
- 研究基于芬兰人群,结果外推至其他种族需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer (PrCa) is one of the most common cancers in men, but little is known about factors affecting its clinical outcomes. Genome-wide association studies have identified more than 170 germline susceptibility loci, but most of them are not associated with aggressive disease. We performed a genome-wide analysis of 185,478 SNPs in Finnish samples (2738 cases, 2400 controls) from the international Collaborative Oncological Gene-Environment Study (iCOGS) to find underlying PrCa risk variants. We identified a total of 21 common, low-penetrance susceptibility loci, including 10 novel variants independently associated with PrCa risk. Novel risk loci were located in the 8q24 (CASC8 rs16902147, OR 1.86, padj = 3.53 × 10-8 and rs58809953, OR 1.71, padj = 4.00 × 10-6; intergenic rs79012498, OR 1.81, padj = 4.26 × 10-8), 17q21 (SP6 rs2074187, OR 1.66, padj = 3.75 × 10-5), 11q13 (rs12795301, OR 1.42, padj = 2.89 × 10-5) and 8p21 (rs995432, OR 1.38, padj = 3.00 × 10-11) regions. Here, we describe SP6, a transcription factor gene, as a new, potentially high-risk gene for PrCa. The intronic variant rs2074187 in SP6 was associated not only with overall susceptibility to PrCa (OR 1.66) but also with a higher odds ratio for aggressive PrCa (OR 1.89) and lower odds for non-aggressive PrCa (OR 1.43). Furthermore, the new intergenic variant rs79012498 at 8q24 conferred risk for aggressive PrCa. Our findings highlighted the power of a population-stratified approach to identify novel, clinically actionable germline PrCa risk loci and strongly suggested SP6 as a new PrCa candidate gene that may be involved in the pathogenesis of PrCa.
引用
- Sipeky C, Tammela TLJ, Auvinen A, et al. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer Prostatic Dis. 2021. PMID: 34012061. doi:10.1038/s41391-021-00378-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。